Moderna intismeran melanoma data at ESMO 2026
Analysis based on 7 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026
The acceptance of late-breaking Phase 3 melanoma data for a Presidential Symposium raises the visibility of Moderna's individualized neoantigen therapy program and could support sentiment toward MRNA shares ahead of the October readout. Merck also stands to benefit as co-developer, though the near-term market reaction likely hinges on the actual data presented rather than the abstract acceptance itself.
Moderna announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology Congress 2026, to be held October 23-27 in Madrid, Spain. The lead presentation, LBA1 INTerpath-001, is a Phase 3 study of intismeran autogene plus pembrolizumab versus pembrolizumab alone for adjuvant treatment of resected stage IIB-IV melanoma, selected for a Presidential Symposium on October 24. Two poster presentations cover adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma from a phase I study, and INTerpath-014, a Phase 3 study in completely resected high-risk stage I NSCLC. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. Moderna will host an investor webcast on October 24 at 7:00 PM CEST. Presenters include Georgina Long, David J. Pinato, and Charu Aggarwal.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard